Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levofloxacin; Levofloxacin; and Levofloxacin marketed formulations · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations | DRUG | - |
Inclusion Criteria: * Men and women * Aged 18 to 55 years * BMI between 18 and 30 kg/m2 * No prescription or over-the-counter medications for previous 14 days * Negative tests for drug and alcohol abuse, HIV, hepatitis B and hepatitis C * and Healthy based on medical history, physical examination, ...
Levofloxacin is a small molecule drug developed by Johnson & Johnson, which trades under the ticker JNJ. It has been studied in a Phase 1 clinical trial in healthy subjects. The specific medical indications for this formulation are undisclosed.
Levofloxacin is developed by Johnson & Johnson, which trades under the ticker JNJ. The company conducted a Phase 1 bioequivalence study of oral suspension, oral solution, and marketed tablet formulations.
Levofloxacin is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials. The trial enrolled 72 healthy subjects and evaluated bioequivalence of oral suspension, oral solution, and marketed tablet formulations.
Levofloxacin has been studied in one completed Phase 1 trial, NCT00602589. The trial was titled "A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects." It enrolled 72 healthy volunteers and was randomized but not double-blind, with an uncontrolled design.
Levofloxacin oral suspension and levofloxacin oral solution are alternative formulations of levofloxacin. The Phase 1 trial NCT00602589 evaluated the bioequivalence of these formulations along with the marketed tablet formulation in healthy subjects.